Stifel Financial Corp Has $1.13 Million Position in Cryoport, Inc. (NASDAQ:CYRX)

Stifel Financial Corp raised its position in Cryoport, Inc. (NASDAQ:CYRX) by 11.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 139,745 shares of the company’s stock after acquiring an additional 13,809 shares during the quarter. Stifel Financial Corp owned approximately 0.28% of Cryoport worth $1,133,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. AXA S.A. lifted its stake in Cryoport by 274.2% in the second quarter. AXA S.A. now owns 873,217 shares of the company’s stock valued at $6,034,000 after acquiring an additional 639,855 shares during the last quarter. Federated Hermes Inc. acquired a new stake in Cryoport in the second quarter valued at $774,000. Point72 Asset Management L.P. acquired a new stake in Cryoport in the third quarter valued at $3,405,000. Intech Investment Management LLC acquired a new stake in shares of Cryoport during the 3rd quarter worth about $105,000. Finally, SG Americas Securities LLC lifted its stake in shares of Cryoport by 278.6% during the 3rd quarter. SG Americas Securities LLC now owns 101,359 shares of the company’s stock worth $822,000 after buying an additional 74,590 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Price Performance

Shares of Cryoport stock opened at $7.86 on Monday. Cryoport, Inc. has a twelve month low of $5.32 and a twelve month high of $20.10. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The company has a 50-day simple moving average of $7.39 and a two-hundred day simple moving average of $8.01. The stock has a market capitalization of $388.53 million, a price-to-earnings ratio of -2.33 and a beta of 1.62.

Insiders Place Their Bets

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $7.46, for a total value of $54,972.74. Following the transaction, the director now directly owns 59,497 shares of the company’s stock, valued at $443,847.62. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jerrell Shelton sold 50,000 shares of the firm’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $6.51, for a total transaction of $325,500.00. Following the completion of the transaction, the chief executive officer now directly owns 731,897 shares in the company, valued at approximately $4,764,649.47. This represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,869 shares of company stock worth $735,673 in the last quarter. 10.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on CYRX. Roth Mkm cut their target price on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, November 8th. UBS Group raised their target price on shares of Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a research note on Friday, October 18th. Finally, Guggenheim began coverage on shares of Cryoport in a research note on Thursday. They set a “buy” rating and a $11.00 target price for the company. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.29.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.